Collegium Pharmaceutical, Inc.
COLL US19459J1043
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Smith Thomas B CMO |
38.42 USD |
17,478 Sold |
671,576 USD |
29/08/2025 | 29/08/2025 |
| Dreyer Scott EX VP |
38.21 USD |
16,389 Sold |
626,171 USD |
18/08/2025 | 18/08/2025 |
| Santini Gino |
37.19 USD |
5,405 Sold |
201,018 USD |
15/08/2025 | 15/08/2025 |
| Dreyer Scott EX VP |
38.03 USD |
4,861 Sold |
184,881 USD |
13/08/2025 | 13/08/2025 |
| Freund John Gordon |
34.36 USD |
11,659 Sold |
400,641 USD |
08/08/2025 | 08/08/2025 |
| Freund John Gordon |
30.62 USD |
6,601 Sold |
202,149 USD |
09/06/2025 | 09/06/2025 |
| Dreyer Scott EX VP |
30.03 USD |
18,881 Sold |
566,983 USD |
20/03/2025 | 21/03/2025 |
| Tupper Colleen EX VP |
30.03 USD |
6,396 Sold |
192,069 USD |
20/03/2025 | 21/03/2025 |
| Tupper Colleen EX VP |
30.00 USD |
1,206 Sold |
36,181 USD |
20/03/2025 | 20/03/2025 |
| Dreyer Scott EX VP |
30.00 USD |
1,927 Sold |
57,811 USD |
20/03/2025 | 20/03/2025 |